Company announcement No. 35 / 2026Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)Copenhagen, Denmark, July 27, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) NASDAQ:ZEAL (CVR-no. 20045078), a biotechnology company transforming the future of metabolic h…
Company announcement – No. 34 / 2026Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated personsCopenhagen, Denmark, July 20, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) NASDAQ:ZEAL (CVR…
Company announcement No. 33 / 2026Zealand Pharma - Transactions related to share buy-back program (week 29, 2026)Copenhagen, Denmark, July 20, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) NASDAQ:ZEAL (CVR-no. 20045078), a biotechnology company transforming the future of metabolic h…
Zealand Pharma A/S (OMXCOP:ZEAL) disclosed week‑26 buybacks under its May–Oct 2026 program, leaving 2,319,482 treasury shares (≈3.24%) of 71,578,758 outstanding, while The Capital Group reported holding 4.79% of ZEAL voting rights in discretionary client accounts as of June 26, 2026.Previous Week R…
